Medical practice loans for New Zealand GP and specialist clinics .

A NZ GP practice acquisition commonly runs $700,000 to $5,000,000 depending on enrolled patient roll, GP count, region, and freehold inclusion. A small 1 to 2 GP practice on a leasehold basis commonly trades at $500,000 to $1.4 million for the operating business. A mid-size 3 to 5 GP practice commonly trades at $1 million to $3 million for the operating business. Acquisitions including freehold premises in Auckland or Wellington commonly push total deal sizes to $2.5 million to $5 million. Specialist clinic acquisitions span a similar range, weighted toward equipment and fit-out value.

Medical Council of New Zealand (MCNZ) registration is the regulatory authority to practise medicine in NZ, issued under the Health Practitioners Competence Assurance Act 2003. Lenders treat current MCNZ registration of the borrowing practitioner (or all partners in a partnership) as a precondition for medical practice finance. Vocational scope (general practice, surgical specialties, etc.) is set by the relevant vocational branch and is part of the lender file. Practitioners under MCNZ Health Practitioners Disciplinary Tribunal action typically face materially tighter lending pools while the action is unresolved.

Primary Health Organisation (PHO) capitation funding is paid monthly by the local PHO to the contracted general practice per enrolled patient under the Capitation Funding Formula, calibrated to age, sex, and other demographic factors. Capitation flows under the Te Whatu Ora Primary Care framework. Lenders treat capitation as the most predictable revenue line in a GP practice funding mix because it flows monthly against a documented enrolled patient roll, and they weight the enrolled patient roll trend in serviceability assessments.

ACC contracted-provider arrangements allow medical practices to treat accident-related conditions and receive ACC treatment payments under the contracted framework. The arrangement adds a known revenue stream alongside PHO capitation, patient co-payments, and any private-pay services. Lenders typically review the ACC contracted-provider agreement and 12 to 24 months of ACC payment history as part of the application file. ACC under-review or recently cancelled contracted-provider arrangements typically tighten the lending pool.

Indicative rates on NZ medical practice finance commonly sit in the 7% to 12% per annum band depending on structure, security, and practice profile. Property-secured commercial mortgages on freehold practice acquisitions for established practitioners sit at the lower end (commonly 7-9%). Major-bank medical-finance team term loans on operating business and partnership buy-ins sit in the middle (commonly 8-10%). Specialist asset finance on clinical equipment sits at the upper end (commonly 9-12%). Final rate is set by the lender after assessment.

Partnership buy-ins are typically structured as a term loan covering 70-80% of the buy-in value with the buyer contributing 20-30% equity, secured by personal guarantees and recorded in a partnership deed amendment setting the new partner's equity share, profit allocation, and exit terms. Term lengths commonly run 7 to 10 years, repaying from the partner's after-tax income share over the term. Vendor finance from the outgoing senior partner is sometimes part of the structure, subordinated to the senior bank facility. Major-bank medical-finance teams have specific lending products for partnership buy-ins.

Medical practice GST treatment is more nuanced than most healthcare segments. Many medical services are GST-exempt under the Goods and Services Tax Act 1985, while related supplies such as medical reports, occupational health assessments, and cosmetic procedures are typically taxable supplies. This mixed-supply position affects input-tax claim ratios on equipment, fit-out, and operating costs, and is typically handled through an apportionment method agreed with the accountant. Where the practice has predominantly exempt supplies, input-tax claims are typically limited to the taxable-supply share. The accountant's confirmation is the standard last step.

Yes. Vendor finance is commonly part of NZ medical practice acquisitions, particularly in GP practice transitions where retiring senior practitioners want a 2 to 5 year transition out of the business. The typical structure has senior bank debt covering 60-80% of the deal value, vendor finance subordinated for 2 to 5 years covering 10-20%, and buyer equity of 10-25%. Vendor finance terms are typically negotiated alongside the senior medical-finance facility, subject to the senior lender's assessment of the combined structure and the partnership transition timeline.

For practice acquisitions, deposits commonly run 10-25% of the deal value depending on practitioner profile, freehold inclusion, and PHO capitation history. Established practices with multi-year stable rolls and clean trading commonly access the lower deposit band; new entrants and acquisitions of practices with declining rolls commonly face higher deposits. For freehold premises purchases, commercial mortgage LVR norms apply (commonly 60-75% LVR). For clinical equipment chattel mortgages, established practices commonly access 0% deposit asset finance.

Major banks BNZ, ANZ, ASB, and Westpac all run dedicated medical-finance teams that recognise the predictable PHO capitation and ACC payment revenue mix and price accordingly. Heartland Bank covers mid-size fit-out term loans and equipment outside the major-bank deal threshold. UDC Finance and a small number of specialist medical-finance brokers cover clinical equipment and partnership-buy-in structures. The right lender pool depends on deal size, security position, and whether the practitioner has an existing major-bank relationship; specialist medical-finance brokers commonly source negotiated pricing across the major-bank pool.

Often yes, particularly after 12 to 24 months of clean trading and repayments where the financial profile has strengthened. Refinancing is commonly used to consolidate multiple medical practice loans (acquisition, equipment, working capital) into a single major-bank facility, to release equity to fund a partnership buy-out or freehold purchase, or to move from specialist lender pricing to major-bank medical-finance pricing once trading history supports it. Early-repayment fees on the original loans and any cross-collateralisation across the practice security are the main considerations.

Where a key practitioner exits a financed medical practice (retirement, illness, partnership dispute, MCNZ Tribunal action), the lender typically engages early on the practice continuity plan and the partnership deed terms governing exit. Major-bank medical-finance facilities commonly include continuity covenants that require the borrower to notify the bank of senior practitioner exits and to demonstrate replacement or roll-down plans. Where the exiting practitioner is the sole borrower, the lender may require sale of the practice, restructure of the loan, or transfer to a new MCNZ-registered owner.

Specialist clinics typically have higher equipment capex (imaging, laser platforms, procedure suites) and a different revenue mix (private-pay procedure fees, health-insurer payments) than GP practices, which lean on PHO capitation and ACC. The finance structure typically blends a chattel mortgage on the specialist equipment with a term loan or commercial mortgage on the clinic premises. Lender comfort tracks vocational scope, fellowship recognition, and the trading record of the practitioner; established specialist clinics with multi-year trading commonly access major-bank medical-finance pricing on equivalent terms to GP practices of similar deal size.

Yes. Clinical equipment can typically be financed under chattel mortgage (practice owns the asset, full GST claimable upfront where applicable) or finance lease (practice leases the asset, GST claimed across rental payments). Operating lease structures are also available on some categories of equipment. The structure choice affects cash-flow timing, balance sheet treatment, and end-of-life rotation rather than total cost over the life of the loan. The accountant is the right person to confirm structure choice and depreciation or rental treatment on the specific practice position.